Atossa Therapeutics (NASDAQ:ATOS) Posts Earnings Results, Beats Estimates By $0.01 EPS

Atossa Therapeutics (NASDAQ:ATOS) issued its quarterly earnings results on Monday. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01, Yahoo Finance reports.

Atossa Therapeutics Price Performance

ATOS stock opened at $1.31 on Wednesday. The company has a market cap of $164.74 million, a P/E ratio of -5.42 and a beta of 1.21. Atossa Therapeutics has a 1 year low of $0.62 and a 1 year high of $2.31. The stock’s fifty day moving average price is $1.24 and its 200-day moving average price is $1.33.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price target on shares of Atossa Therapeutics in a research report on Monday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Atossa Therapeutics in a research note on Thursday, June 20th. StockNews.com lowered Atossa Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday. Finally, Ascendiant Capital Markets boosted their price objective on Atossa Therapeutics from $6.00 to $6.25 and gave the company a “buy” rating in a research note on Thursday, June 6th.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.